Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAVIG-1
2024-514567-26-00Phase 2Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Sep 2024
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Peptide A49, A52 peptide and tgf-β2 antisense oligonucleotide in glioblastoma (GBM), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoints: Safety and Immune efficacy: anti-TERT specific T cell responses. Planned start Sep 2024; status: authorised.
02
Drugs
Peptide A49A52 peptidetgf-β2 antisense oligonucleotide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2024-514567-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514567-26-00.